PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1944422
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1944422
Hemorrhagic Stroke Treatment Devices Market size was valued at US$ 1,084.23 Million in 2024, expanding at a CAGR of 7.12% from 2025 to 2032.
The hemorrhagic stroke treatment devices market focuses on medical devices used to manage bleeding-type strokes, mainly intracerebral hemorrhage and subarachnoid hemorrhage, including cases linked to ruptured brain aneurysms. These events are treated as medical emergencies, and the choice of devices can affect how quickly bleeding is controlled, whether re-bleeding is prevented, and how patients recover over time. The market includes endovascular tools such as coils, flow diverters, and stent-assisted systems used to seal aneurysms from inside the blood vessel, along with surgical tools like aneurysm clips used in open procedures when required.
Demand is connected to factors such as aging populations, high blood pressure and vascular risk, and the expansion of hospitals with neurointerventional capabilities. Buying decisions in this market are usually based on clinical outcomes, safety and complication rates, how easy devices are to use in complex anatomy, compatibility with existing hospital systems, and the overall cost per treated case, which makes product performance and evidence an important part of vendor competition.
Hemorrhagic Stroke Treatment Devices Market- Market Dynamics
High Stroke Burden and Better Access to Stroke Centers Are Increasing Use of Hemorrhagic Treatment Devices
A major driver for the hemorrhagic stroke treatment devices market is the ongoing stroke burden and the steady expansion of organized stroke care, which increases the number of patients reaching hospitals that can perform aneurysm repair and other neurovascular procedures. Stroke remains a major public health issue in the U.S.: According to the U.S. Centers for Disease Control and Prevention (CDC, stroke updates published during 2023-2024), stroke affects hundreds of thousands of people each year and continues to rank among the leading causes of long-term disability, which keeps hospitals focused on improving acute stroke pathways and clinical outcomes. Globally, the overall mortality impact stays high: According to World Health Organization (WHO) updates released during 2022-2024, stroke remains among the top causes of death worldwide, with hypertension and aging populations continuing to support risk levels. System changes also matter because routing and treatment networks influence procedure volume at capable sites: According to U.S. government and state public health/EMS stroke-system materials compiled across 2020-2024 (including HRSA-supported and state stroke program reporting), more regions have strengthened stroke triage and destination protocols, which increases the concentration of severe stroke cases at higher-level centers where endovascular and surgical device use is more common. For hospital buyers and neurointerventional teams, this directly supports demand for coils, flow diverters, stents, and clipping systems that can reduce re-bleeding risk, improve procedural safety, and help shorten ICU and hospital stays.
More hemorrhagic stroke care is moving toward catheter-based treatment pathways, especially for aneurysm-related bleeding, because these procedures can be performed faster in specialized centers and can reduce the burden of open surgery in many cases. The overall volume base remains large: According to the U.S. Centers for Disease Control and Prevention (CDC, stroke information updated during 2023-2024), stroke affects hundreds of thousands of people each year in the United States, keeping emergency stroke workflows active and supporting steady use of neurovascular devices in hospitals that can treat complex cases. Access factors also keep improving because stroke systems continue to formalize routing and care networks: According to state health department stroke-system plans and EMS destination protocol updates published during 2020-2024, more regions have implemented structured triage rules that direct severe stroke patients to higher-capability stroke centers, which increases the number of hemorrhagic cases evaluated for endovascular repair using coils, stents, and flow-diversion technologies. In purchasing terms, this pushes demand toward devices that can navigate difficult anatomy, simplify procedure steps, and reduce complications that extend ICU stays.
Clinical needs also differ based on whether bleeding occurs inside the brain tissue or around the brain, and this affects which tools are required and how quickly definitive treatment must happen. The broader disease burden remains serious globally: According to World Health Organization (WHO, updates released during 2022-2024), stroke continues to rank among the top causes of death worldwide, and long-term drivers such as hypertension and aging populations keep the risk environment high. Hospital workflow pressure supports faster diagnosis and treatment readiness: According to the U.S. Centers for Medicare & Medicaid Services (CMS) inpatient and quality program updates released during 2020-2024, hospitals operate under ongoing quality and reporting expectations that reinforce standardized acute-care processes, which support investment in stroke-team capability and procedure-ready device availability. For hospital committees and neurointerventional teams, this generally translates into demand for device platforms that improve speed and consistency during aneurysm securing and reduce the risk of re-bleeding and procedure-related complications.
Hemorrhagic Stroke Treatment Devices Market- Geographical Insights
Geographically, demand for hemorrhagic stroke treatment devices tends to be higher in healthcare systems that have organized stroke networks and enough specialized hospitals to run neurointerventional services around the clock. North America and parts of Europe generally benefit from established triage systems and strong hospital spending on advanced procedures, while Asia-Pacific has a large patient base and is expanding higher-level hospital capabilities in major cities. The size of the clinical need remains a major baseline driver: According to the U.S. Centers for Disease Control and Prevention (CDC, updates published during 2023-2024), stroke affects hundreds of thousands of people each year in the United States, which supports consistent demand for aneurysm-repair tools and other neurovascular devices in stroke-capable hospitals. The global burden also stays significant: According to World Health Organization (WHO, updates released during 2022-2024), stroke remains among the top causes of death worldwide, keeping long-term pressure on emergency care capacity and the devices used to treat high-acuity bleeding events.
United States Hemorrhagic Stroke Treatment Devices Market- Country Insights
The United States stands out as a strong country market because of scale, strong reimbursement capacity, and a large base of hospitals that maintain stroke readiness and can adopt newer endovascular technologies. High stroke burden continues to support procedure activity: According to CDC (2023-2024 stroke updates), stroke remains a leading cause of serious disability and still impacts hundreds of thousands of people per year, which keeps hospital investment focused on faster diagnosis and intervention capability. Hospital incentives and workflow standards also influence procurement: According to the U.S. Centers for Medicare & Medicaid Services (CMS) inpatient payment and quality-program updates released during 2020-2024, hospitals operate under ongoing reporting and performance expectations that reinforce standardized acute stroke pathways, supporting purchasing of endovascular device inventories and surgical tools needed for hemorrhagic stroke care.
The competitive landscape is led by companies with deep neurovascular portfolios and strong clinical support, since success depends on evidence, physician training, and consistent device performance in complex anatomy. Medtronic plc and Stryker Corporation are often referenced for broad neurovascular product lines and strong positioning in major stroke centers, which helps with hospital standardization and contracting. Terumo Corporation and MicroVention, Inc. are typically linked with catheter and coil systems designed for controlled deployment and access in challenging vessels. Penumbra, Inc. is commonly associated with aspiration and procedure-support systems used in neurointervention settings where speed matters. Boston Scientific Corporation, Abbott Laboratories, and Johnson & Johnson Services, Inc. are usually seen as large-scale competitors with distribution strength and clinical infrastructure, supporting adoption across wider hospital networks. Across these vendors, competitive strength generally comes down to device deliverability, complication management, training programs, and post-market clinical data, which are the main factors used by hospital committees when selecting hemorrhagic stroke treatment platforms.
In November 2024, AIIMS Delhi and a consortium of 16 Indian hospitals (public and private hospitals providing advanced stroke care) partnered to launch the GRASSROOT clinical trial to evaluate Gravity Medical Technology's (stroke treatment device developer) stent-retriever designed for mechanical thrombectomy in Indian patients with large vessel occlusion stroke; the program was positioned around India's high stroke burden of about 1.7 million strokes annually, an estimated 375,000 patients who could benefit each year from interventional stroke treatment, and the gap that only about 4,500-5,000 patients received thrombectomy in 2023 due to access and cost, with a stated goal to bring device pricing down to roughly one-quarter of current levels.
In May 2024, IIIT Bangalore (research and engineering institute) unveiled XoRehab (an IoT-enabled rehabilitation wheelchair device) developed through the Centre for the Internet of Ethical Things with support from government and international partners, designed to help stroke patients continue physiotherapy after hospital discharge using surface EMG tracking and a 9-degree-of-freedom assistive suit for upper and lower limb movement; the device was positioned for hospital purchase at around ₹85,000-₹90,000 with a rental model to improve access for patients who struggle to attend frequent in-person therapy sessions.
In September 2021, Hyperfine, Inc. (medical imaging technology company) announced results from a Yale New Haven Hospital study of its FDA-cleared portable MRI system Swoop, showing performance for hemorrhagic stroke detection including 96.6% specificity (85/88) for blood-negative cases and 80.4% sensitivity (45/56) for intracerebral hemorrhage detection across 144 exams, with later-study software versions reaching 90.5% overall accuracy and 85.3% sensitivity (29/34); the company highlighted the bedside design as a way to reduce ICU patient transport risks and support faster stroke assessment where conventional CT/MRI access is limited.